Related Experiment Video
Updated: Apr 22, 2026
07:12
Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
Published on: October 26, 2017
7.0K
Targeting nucleus DNA with a cyclometalated dipyridophenazineruthenium(II) complex
Huaiyi Huang1, Pingyu Zhang, Bole Yu
1MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Optoelectronic Materials and Technologies, School of Chemistry and Chemical Engineering, Sun Yat-Sen University , Guangzhou, 510275, China.
Journal of Medicinal Chemistry
|October 15, 2014
Summary
A novel ruthenium(II) complex, [Ru(bpy)(phpy)(dppz)](+), shows potent anticancer activity by accumulating in cancer cell nuclei and disrupting DNA binding. This DNA-specific complex offers a promising alternative to cisplatin.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Ruthenium(II) complexes are explored as anticancer agents due to their inert nature.
- Cyclometalated ruthenium(II) complexes offer unique structural and electronic properties.
- Understanding the cellular uptake and DNA interaction mechanisms is crucial for developing effective cancer therapies.
Purpose of the Study:
- To synthesize and characterize a novel cyclometalated ruthenium(II) complex, [Ru(bpy)(phpy)(dppz)](+).
- To evaluate the in vitro anticancer activity of [Ru(bpy)(phpy)(dppz)](+) against various cancer cell lines and 3D tumor spheroids.
- To elucidate the molecular mechanisms underlying the anticancer effects of the complex, focusing on DNA binding and transcription factor inhibition.
Main Methods:
- Synthesis and characterization of the cyclometalated ruthenium(II) complex.
- Cellular uptake and subcellular localization studies using fluorescence microscopy.
- Anticancer activity screening using IC50 assays against cancer cell lines and 3D tumor spheroids.
- DNA binding affinity studies and investigation of transcription factor NF-κB binding disruption.
Main Results:
- The complex [Ru(bpy)(phpy)(dppz)](+) demonstrated rapid uptake by cancer cells, with significant accumulation in the nucleus (approx. 90% within 2 h).
- The complex exhibited significantly lower IC50 values compared to cisplatin against tested cancer cell lines and superior potency against 3D tumor spheroids.
- High DNA binding affinity was observed, leading to effective disruption of transcription factor NF-κB binding to DNA.
- Inhibition of cellular transcription and induction of irreversible cancer cell apoptosis were confirmed.
Conclusions:
- The cyclometalated ruthenium(II) complex [Ru(bpy)(phpy)(dppz)](+) possesses potent anticancer properties.
- Its efficacy stems from rapid nuclear accumulation, high DNA binding affinity, and disruption of critical cellular processes like transcription.
- This study provides valuable insights into the anticancer mechanisms of DNA-specific ruthenium(II) polypyridyl complexes, highlighting their potential as novel therapeutic agents.
